You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,622,277


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,622,277
Title:Process for the production of biodegradable, functionalised polymer particles, and use thereof as pharmaceutical supports
Abstract: The invention relates to a method for producing biodegradable, functionalised polymer particles, and to the use of the same as medicament carriers.
Inventor(s): Rehm; Bernd Helmut Adam (Palmerston North, NZ)
Assignee: Massey University (Palmerston North, NZ)
Application Number:10/525,955
Patent Claims:1. A process for producing polyhydroxy carboxylate particles having surface-bound proteins, the process comprising: A) providing a cell comprising at least one gene that codes for a fusion protein, the fusion protein comprising (a) a polymer synthase from a microorganism of the genera Ralstonia, Alcaligenes, Pseudomonas, Aeromonas, or Thiocapsa, and (b) at least one protein selected from an oligopeptide, antibody, non-catalytic protein or enzyme, fused with the N-terminus of the polymer synthase, the polymer synthase comprising a polymer particle binding domain; B) cultivating the cell in a culture medium so that the cell produces the fusion protein from the at least one gene and produces polymer particles comprising polyhydroxy carboxylate, wherein the polymer particle binding domain of the fusion protein is bound to a polymer particle; and C) separating the polymer particles from the cultivated cells to produce a composition comprising polyhydroxy carboxylate particles having surface-bound proteins.

2. A process according to claim 1, wherein the polymer synthase is from Ralstonia eutropha, Pseudomonas oleovorans, Pseudomonas putida, Pseudomonas aeruginosa, Aeromonas punctata or Thiocapsa pfennigii.

3. A process according to claim 1, wherein the culture medium comprises at least one hydroxy fatty acid.

4. A process according to claim 1, wherein a hydroxy fatty acid is added to the culture medium in such a quantity that it is sufficient to ensure control of the size of the polymer particles.

5. A process according to claim 1, wherein the cell is a microorganism selected from the genera consisting of Escherichia, Ralstonia, Alcaligenes, Pseudomonas, Halobiforma Aeromonas, and Thiocapsa.

6. A process according to claim 1, wherein the polymer particles have a diameter of 10 nm to 3 .mu.m.

7. A process according to claim 1, wherein the polymer particles have a diameter of 10 nm to 900 nm.

8. A process according to claim 1, wherein the polymer particles have a diameter of 10 nm to 100 nm.

9. A process according to claim 1, wherein at least one dye is added to the culture medium and incorporated into the particles.

10. A process according to claim 1, further comprising D) chemically modifying the polymer synthase by contacting the polymer synthase with a coupling reagent.

11. A process according to claim 1, further comprising D) binding a biologically active substance to the fusion protein, wherein the biologically active substance is selected from i) dideoxyinosine, floxuridine, 6-mercaptopurine, doxorubicin, daunorubicin, 1-darubicin, cisplatin, methotrexate, taxol, antibiotics, anticoagulants, germicides, antiarrhythmic agents and active ingredient precursors or derivatives thereof, or ii) insulin, calcitonin, ACTH, glucagons, somatostatin, somatotropin, somatomedin, parathyroid hormone, erythropoietin, hypothalamic release factors, prolactin, thyroid-stimulating hormone, endophins, enkephalins, vasopressins, non-naturally occurring opiates, superoxide dismutase, antibodies, interferons, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, trypsin, chymotrypsin or pepsin, or iii) an oligopeptide, antibody, non-catalytic protein or enzyme.

12. A process according to claim 1, wherein the protein is selected from insulin, calcitonin, ACTH, glucagons, somatostatin, somatotropin, somatomedin, parathyroid hormone, erythropoietin, hypothalamic release factors, prolactin, thyroid-stimulating hormone, endophins, enkephalins, vasopressins, non-naturally occurring opiates, superoxide dismutase, antibodies, interferons, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, trypsin, chymotrypsin or pepsin.

13. A process according to claim 1, wherein the protein is an antibody.

14. A process according to claim 10, wherein the coupling reagent is selected from the group consisting of bis(2-oxo-3-oxazolydinyl)phosphonic chloride (BOP-Cl), bromotrispyrrolidinophosphonium hexafluorophosphate (PyBroP), benzotriazol-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate (PyBOP), n-hydroxysuccinimide biotin, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), dicyclohexylcarbodiimide, disuccinimidyl carbonate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), bis(2-oxo-3-oxazolydinyl)phosphine, diisopropylcarbodiimide (DIPC), 2-(1H-benzotrioxazolyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 2-(5-norbornene-2,3-dicarboxyimido)-1,1,3,3-tetramethyluronium tetrafluoroborate (TNTU), para-nitrophenylchloroformate, and O-(n-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU).

15. A process according to claim 1, wherein the cell comprises two or more of the at least one gene that codes for a fusion protein.

16. A process according to claim 1, wherein the cell comprises three or more of the at least one gene that codes for a fusion protein.

17. A process according to claim 1, wherein one or more of the surface-bound proteins are removed from the polymer particles.

18. A process according to claim 1, wherein the composition consists essentially of polymer particles having surface-bound proteins.

19. A method of binding a second protein comprising A) providing a composition of polymer particles produced by a method according to claim 1, wherein optionally a coupling reagent is bound to the fusion protein, and B) contacting the composition with a sample comprising a second protein selected from an oligopeptide, antibody, non-catalytic protein or enzyme so that the protein or the coupling reagent binds the second protein.

20. A process according to claim 1, wherein the cell further comprises one or more genes that code for one or more additional fusion proteins, the one or more additional fusion proteins comprising (a) a polymer particle binding domain, or (b) a protein involved in the formation of the polymer particles, the protein comprising a polymer particle binding domain, the additional fusion protein further comprising (i) at least one protein selected from an oligopeptide, antibody, non-catalytic protein or enzyme, or (ii) at least one binding domain capable of binding one or more proteins or one or more coupling reagents, wherein the protein is selected from an oligopeptide, antibody, non-catalytic protein or enzyme, or (iii) at least one protein and at least one binding domain capable of binding one or more biologically active substances or one or more coupling reagents, wherein the protein is selected from an oligopeptide, antibody, non-catalytic protein or enzyme, or (iv) a combination thereof.

21. A process according to claim 5, wherein the microorganism is selected from the group consisting of Ralstonia eutropha, Alcaligenes latus, Escherichia coli, Pseudomonas fragi, Pseudomonas putida, Pseudomonas oleovorans, Pseudomonas aeruginosa, Pseudomonas fluorescens, Halobiforma haloterrestris, Aeromonas punctata and Thiocapsa pfennigii.

22. A process according to claim 20, wherein the at least one gene that codes for a protein involved in the formation of polymer particles is selected from the group consisting of a gene coding for a phaA thiolase, a gene coding for a phaB ketoacyl reductase, a gene coding for a polymer depolymerase, a gene coding for a polymer regulator, a gene coding for a polymer synthase, and a gene coding for a particle size-determining protein, or a combination thereof.

Details for Patent 7,622,277

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2022-08-30
Nps Pharmaceuticals, Inc. NATPARA parathyroid hormone For Injection 125511 01/23/2015 ⤷  Try a Trial 2022-08-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.